A multicenter, randomized phase III trial comparing second-line chemotherapy (SLC) plus best supportive care (BSC) with BSC alone for pretreated advanced gastric cancer (AGC).

Park, S. H.; Lim, Do Hyoung; Park, K.; Lee, S.; Oh, SuA; Kwon, Han Sung; Kang, Junmo; Hwang, In Gyu; Lee, J.; Park, J. O.; Park, Y. S.; Lim, Hyunji; Kang, Wenyi

doi:10.1200/jco.2011.29.15_suppl.4004

Cited by 17 publications

(20 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Moreover, active and tolerable salvage chemotherapy can improve QOL and clinical outcomes in a certain proportion of selected patients [41]. A multicenter, randomized phase III trial comparing second-line chemotherapy plus BSC with BSC alone for pretreated AGC has been presented in an abstract [42].…”

Section: Discussionmentioning

confidence: 99%

“…At the 2011 American Society of Clinical Oncology (ASCO) annual meeting, a large, prospective, multicenter, randomized phase III study to assess whether a benefit of second-line chemotherapy exists was reported. This trial compared active treatment (docetaxel or irinotecan) with BSC and reported a survival benefit of second-line chemotherapy [42]. Moreover, further studies might be designed to consider the regimens used during the whole treatment course, similar to the regimens used for colorectal cancer, for which the three drugs, 5-FU, irinotecan, and oxaliplatin, should all be used.…”

Section: Second-line Chemotherapy For Agc In Korea 351mentioning

confidence: 99%

See 1 more Smart Citation

Second-line chemotherapy for advanced gastric cancer in Korea

et al. 2012

View full text Add to dashboard Cite

Stomach cancer is still one of the most prevalent malignancies and is the main cause of cancer deaths worldwide. The outcome for patients with metastasis, as well as for those with tumor recurrence, is dismal, with median survival time not greater than a year. Patients with unresectable locally advanced or metastatic lesions have been treated with systemic chemotherapy, and several randomized studies have demonstrated the benefit of chemotherapy compared with best supportive care. Recently, randomized phase III trials have presented a benefit of second-line chemotherapy compared with supportive care alone. However, it is not known at present which drug is the most effective in this setting. In Korea, the practice of offering second-line treatment to patients with advanced gastric cancer (AGC) is common, and many prospective clinical trials investigating clinical outcomes of second-line chemotherapy have been reported. Therefore, to define the potential role of second-line chemotherapy and to help to select an effective regimen, we review the published Korean prospective data concerning the use of chemotherapy in the second-line setting for the treatment of AGC. No phase III trials but 20 phase II trials were identified. The benefit of second-line chemotherapy in AGC has indirect evidence considering prolongation of progression-free survival (PFS) and improvement of the response rate. Taxanes, irinotecan, and oxaliplatin have been studied much and might be promising drugs considering crossresistance to a 5-fluorouracil and cisplatin combination (FP). A large, prospective, multicenter, randomized phase III study is warranted to select the most effective second-line chemotherapeutic agents.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Second-line Chemotherapy For Agc In Korea 351mentioning

confidence: 99%

Second-line chemotherapy for advanced gastric cancer in Korea

et al. 2012

View full text Add to dashboard Cite

show abstract

“…In the study performed by Park . 2002 patients with advanced gastric cancer who showed progression with first-line therapy with fluoropyrimidines and a platinum agent received docetaxel or irinotecan (Park et al, 2011). In the intent-to-treat population, a significant difference in OS (5.1 months for Second-line therapy v 3.8 months for BSC) was observed (hazard ratio, 0.63; 95% confidence interval, 0.47-0.86; P=0.004).…”

Section: Discussionmentioning

confidence: 99%

Second-Line Irinotecan after Cisplatin, Fluoropyrimidin and Docetaxel for Chemotherapy of Metastatic Gastric Cancer

Küçükzeybek¹,

Dirican²,

Erten³

et al. 2012

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Aim: Tumors of upper gastrointestinal tract are among the cancers that have a quite lethal course. Cytotoxic chemotherapy is the most efficient therapeutic modality for metastatic gastric cancer. In patients who do not respond to first-line treatment, the response rate to second-line therapies is generally low and the toxicity rates high. This study concerned the efficacy and the side effect profile of second-line therapy with irinotecan in the patients who were being followed-up with the diagnosis of metastatic gastric cancer in İzmir, Turkey.

show abstract

“…This strategy could be especially appropriate in patients who may be unable to tolerate the toxicity of combination therapy [26]. Given the natural history of advanced gastric cancer, and the availability of new active drugs in this lethal disease, second-line chemotherapy has become an option for some patients [27,28], and irinotecan or docetaxel are commonly used in this setting. However, a three-drug docetaxel-containing regimen as first-line chemotherapy is to be considered a valuable approach.…”

Section: Discussionmentioning

confidence: 99%

Sequential chemotherapy with cisplatin, leucovorin, and 5-fluorouracil followed by docetaxel in previously untreated patients with metastatic gastric cancer: a phase II study

Catalano

Vincenzi²,

Giordani

et al. 2012

Gastric Cancer

View full text Add to dashboard Cite

Background The combination of docetaxel, cisplatin, and 5-fluorouracil (5-FU) has demonstrated a survival advantage over cisplatin and 5-FU, but with substantial hematological toxicity. We aimed to evaluate the efficacy and toxicity of a sequential regimen with cisplatin, leucovorin, and 5-FU (PLF) followed by docetaxel in metastatic gastric cancer patients. Methods Treatment consisted of 4 cycles of biweekly PLF (cisplatin 50 mg/m 2 as a 30-min infusion on day 1, leucovorin 200 mg/m 2 in a 2-h infusion, and 5-FU 2,800 mg/m 2 in a 48-h continuous infusion starting on day 1) followed, in cases of response or stable disease, by 3 cycles of docetaxel (75 mg/m 2 , every 3 weeks). Results Thirty-four patients were enrolled, with an average age of 64 years (range 34-69). The main cumulative grade 3-4 toxicities were: neutropenia (38.2%), febrile neutropenia (11.8%), and fatigue (14.7%). After the planned 7 cycles of treatment, the overall response rate was 38.2% (95% confidence interval [CI] 21.9-54.6), with 3 complete and 10 partial responses. Median progression-free survival and overall survival were 4.8 and 10.6 months, respectively.Conclusions For patients with metastatic gastric cancer, the sequential administration of cisplatin, leucovorin, 5-FU, and docetaxel may be an effective palliative option and offers a far more favorable toxicity profile than the simultaneous use of docetaxel, cisplatin, and 5-FU.

show abstract

A multicenter, randomized phase III trial comparing second-line chemotherapy (SLC) plus best supportive care (BSC) with BSC alone for pretreated advanced gastric cancer (AGC).

Cited by 17 publications

References 0 publications

Second-line chemotherapy for advanced gastric cancer in Korea

Second-line chemotherapy for advanced gastric cancer in Korea

Second-Line Irinotecan after Cisplatin, Fluoropyrimidin and Docetaxel for Chemotherapy of Metastatic Gastric Cancer

Sequential chemotherapy with cisplatin, leucovorin, and 5-fluorouracil followed by docetaxel in previously untreated patients with metastatic gastric cancer: a phase II study

Contact Info

Product

Resources

About